V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160011900 | 160005668 | 1.74 | 73 | Palliative (P) | 2016-11-23 | 2016-12-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101184774 |
| 160011902 | 160005669 | 1.7 | 78.2 | Palliative (P) | 2018-12-01 | 2018-12-13 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | DOXORUBICIN | 100910830 |
| 160011906 | 160005670 | 1.73 | 95 | Curative (C) | 2019-05-06 | 2019-05-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101444135 |
| 160011908 | 160005671 | 1.81 | 72.25 | Palliative (P) | 2017-04-16 | 2017-04-16 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 01 | N | PACLITAXEL | 100433536 |
| 160011910 | 160005672 | 1.82 | 80 | Palliative (P) | 2017-01-09 | 2017-01-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100562507 |
| 160011911 | 160005673 | 1.73 | 71 | Palliative (P) | 2019-03-16 | 2019-03-24 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100335096 |
| 160011913 | 160005674 | 1.78 | 70 | Curative (C) | 2018-10-22 | 2018-11-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101344699 |
| 160011915 | 160005675 | 1.73 | 74.4 | Palliative (P) | 2019-08-25 | 2019-09-04 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | IPM | 100714772 |
| 160011917 | 160005676 | null | null | null | 2018-03-25 | 2018-04-07 | NB HRNBL-1 COJEC Ind COURSE A | 02 | null | EURO-EWING | 101465451 |
| 160011920 | 160005677 | 0 | 58 | Palliative (P) | 2022-03-26 | 2022-03-26 | ETOPOSIDE + IFOSFAMIDE | 02 | N | DOXORUBICIN | 101283956 |
| 160011922 | 160005678 | 1.81 | 67.9 | 03 | 2019-08-25 | 2019-08-31 | null | N | N | ETOP 13-18 BEAT-MESO TRIAL | 100414893 |
| 160011923 | 160005679 | 1.8 | 93.4 | Curative (C) | 2015-12-17 | 2016-01-16 | Doxorubicin + Olaratumab | 01 | N | LIPOSOMAL DAUNORUBICIN | 100292073 |
| 160011924 | 160005680 | 1.76 | 96.6 | Neo-adjuvant (N) | 2017-06-30 | 2017-07-01 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101650182 |
| 160011927 | 160005681 | 1.55 | 76 | Palliative (P) | 2018-01-30 | 2018-02-05 | Doxorubicin + Ifosfamide | null | N | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 101634702 |
| 160011928 | 160005682 | 1.78 | 79.5 | Neo-adjuvant (N) | 2017-01-19 | 2017-01-19 | Carboplatin + Paclitaxel (3 weekly) | N | N | TRIAL | 100754008 |
| 160011930 | 160005683 | null | null | 03 | 2019-06-03 | 2019-07-12 | ETOPOSIDE + IFOSFAMIDE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101597973 |
| 160011931 | 160005684 | 1.56 | 61 | Neo-adjuvant (N) | 2018-03-29 | 2018-03-29 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | null | EW EUROEWING 2012 ARM B VDC | 100837576 |
| 160011933 | 160005685 | 1.6 | 53.2 | Adjuvant (A) | 2017-03-04 | 2017-03-08 | EW EuroEwing 2012 Arm B VDC | N | N | DOXORUBICIN | 100462842 |
| 160011934 | 160005686 | 1.55 | 91 | Disease modification (D) | 2018-11-16 | 2018-11-16 | Trial Unspecified | 02 | N | CARBOPLATIN + PACLITAXEL | 100920406 |
| 160011936 | 160005687 | 1.68 | 83.5 | Palliative (P) | 2018-02-03 | 2018-02-10 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101814689 |
| 160011938 | 160005688 | 1.73 | 70.5 | null | 2019-11-27 | 2019-12-25 | null | 02 | N | TALIMOGENE LAHERPAREPVEC | 100718439 |
| 160011941 | 160005690 | 1.8 | 96.6 | Palliative (P) | 2018-05-14 | 2018-05-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101534980 |
| 160011942 | 160005691 | null | 89 | Curative (C) | 2016-09-27 | 2016-10-15 | Cisplatin + Pemetrexed | Y | N | CISPLATIN + PEMETREXED | 101322762 |
| 160011945 | 160005692 | 1.61 | 57.5 | Neo-adjuvant (N) | 2019-10-22 | 2019-10-30 | VINORELBINE | N | N | DOXORUBICIN | 101709846 |
| 160011948 | 160005693 | 1.7 | 90 | Palliative (P) | 2017-11-28 | 2017-11-28 | Pemetrexed | null | N | DOXORUBICIN + IFOSFAMIDE | 101247845 |
| 160011949 | 160005694 | 1.74 | 49.6 | Curative (C) | 2018-05-09 | 2018-05-29 | Doxorubicin 75mg/m2 | 02 | N | CISPLATIN + GEMCITABINE | 100037829 |
| 160011950 | 160005695 | null | null | null | 2017-04-14 | 2017-05-05 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 101493090 |
| 160011952 | 160005696 | 1.75 | 85.2 | Palliative (P) | 2018-10-19 | 2018-11-01 | null | 02 | N | PACLITAXEL | 100295633 |
| 160011955 | 160005697 | 1.63 | 73.2 | Neo-adjuvant (N) | null | 2016-12-28 | BEP 5 Day | 02 | N | TRIAL UNSPECIFIED | 100135394 |
| 160011959 | 160005698 | 1.64 | 71.4 | Palliative (P) | 2021-11-05 | 2021-11-23 | LENVATINIB | 01 | Y | DOXORUBICIN + IFOSFAMIDE | 100653094 |
| 160011963 | 160005699 | 1.68 | 78 | Palliative (P) | 2019-03-16 | 2019-03-25 | Docetaxel + Gemcitabine (prior RT) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100407773 |
| 160011966 | 160005700 | 1.69 | 98.4 | Neo-adjuvant (N) | 2017-04-27 | 2017-05-13 | Paclitaxel 7 day | 02 | null | DOXORUBICIN + OLARATUMAB | 100518195 |
| 160011967 | 160005701 | 1.87 | 62.3 | Palliative (P) | 2018-05-20 | 2018-06-11 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101757732 |
| 160011968 | 160005702 | 1.65 | 84.6 | Palliative (P) | 2019-08-24 | 2019-09-07 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101480548 |
| 160011971 | 160005703 | 1.65 | 86.5 | null | 2018-06-04 | 2018-06-05 | NB Low/Interm risk guidelines Carbo/Etop | 2 | null | WT SIOP 2002 01 POST OP CARBO, ETOP | 101645339 |
| 160011973 | 160005704 | 1.76 | 60.5 | Neo-adjuvant (N) | 2016-03-31 | 2016-04-19 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100453317 |
| 160011974 | 160005705 | 1.8 | 84.4 | null | 2018-12-23 | 2019-01-06 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101795818 |
| 160011977 | 160005706 | 1.64 | 9.4 | Palliative (P) | 2017-10-25 | 2017-10-26 | Doxorubicin + Ifosfamide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100634324 |
| 160011978 | 160005707 | 1.53 | 32.8 | Palliative (P) | 2019-05-08 | 2019-05-15 | DOXORUBICIN | null | N | BEVACIZUMAB | 100213646 |
| 160011981 | 160005708 | 1.82 | 89.6 | Palliative (P) | 2019-08-08 | 2019-08-11 | Trial Unspecified | 02 | N | ENZALUTAMIDE | 101871181 |
| 160011982 | 160005709 | 1.72 | 79.9 | null | 2017-05-19 | 2017-06-17 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100678747 |
| 160011983 | 160005710 | 1.69 | 74.45 | Palliative (P) | null | 2016-12-14 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101162629 |
| 160011986 | 160005711 | 1.8 | 73.4 | Palliative (P) | 2018-03-01 | 2018-03-08 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 101545930 |
| 160011988 | 160005712 | 0 | 93.5 | Neo-adjuvant (N) | 2019-03-24 | 2019-04-04 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101416758 |
| 160011992 | 160005713 | 1.69 | 126.4 | Palliative (P) | 2020-04-07 | 2020-04-17 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | IMATINIB | 101523840 |
| 160011993 | 160005714 | 1.6 | 6.6 | Curative (C) | 2013-10-19 | 2013-10-30 | null | N | N | EW EUROEWING 2012 ARM A VIDE | 101618636 |
| 160011995 | 160005715 | 1.78 | 78.6 | Neo-adjuvant (N) | 2017-06-27 | 2017-07-03 | ETOP 13-18 BEAT-meso Trial | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100136868 |
| 160011996 | 160005716 | 1.54 | 86.1 | Palliative (P) | 2021-09-04 | 2021-09-11 | IPILIMUMAB + NIVOLUMAB | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101708836 |
| 160011997 | 160005717 | 1.69 | 85 | Palliative (P) | 2019-04-10 | 2019-04-24 | Doxorubicin 75mg/m2 | null | N | DOXORUBICIN + IFOSFAMIDE | 100271327 |
| 160011998 | 160005718 | 1.73 | 71 | Palliative (P) | 2018-09-12 | 2018-09-16 | Trial Unspecified | N | N | TRIAL UNSPECIFIED | 100423468 |